FBIOP Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
NASDAQ · Biotechnology · Lihat di SEC EDGAR ↗ tutup Okt 2, 2026 10-K/10-Q Agu 13, 2026
$16,86
· % dari rentang 52 mgg
· di atas terendah
· ke tinggi
$6,27rendah 52m
$21,43tinggi 52m
Kapitalisasi Pasar (MRQ)
$562M
P/E (TTM)
6.2
EPS (TTM)
$2.70
Pendapatan (TTM)
$68M
lencana Anda
Rentang 52M
$6–$21
Peringkat Analis
BUY
Target Harga
·
P/E
6.2
ROE
107.5%
Margin Laba Bersih
163.3%
Strip lencana Anda kosong — sematkan metrik di mana saja di halaman ini.
FBIOP Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$16.86
Kapitalisasi Pasar (MRQ)
$562M
P/E (TTM)
6.2
EPS (TTM)
$2.70
Pendapatan (TTM)
$68M
Imbal Hasil Dividen
0.12%
ROE (TTM)
107.5%
D/E Utang/Ekuitas (MRQ)
0.0
Rentang 52M
$6–$21
FBIOP Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
rentang
batang
Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.
Tentang Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Tinjauan perusahaan dari Wikipedia
Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.
History
The company was founded in 2006 under the name Coronado Biosciences, initially as an oncology company. In 2011, it was announced that Coronado raised $47.4 million in funding. Shortly thereafter it became a public company by registering all of its private shares as common stock. The company changed its name to Fortress Biotech in April 2015.
In November 2019, Fortress Biotech was ranked number 10 in the 2019 Deloitte Technology Fast 500 annual rankings.
Subsidiaries
Fortress Bio has 10 biopharmaceutical subsidiary companies which cover a range of medical therapy areas, including potential cancer treatments and therapies for rare diseases and conditions. These subsidiaries include Aevitas Therapeutics (formed in 2017), Avenue Therapeutics (formed in 2015), Caelum Biosciences (formed in 2017), Cellvation (formed in 2016), Checkpoint Therapeutics (formed in 2015), Cyprium Therapeutics (formed in 2017), Helocyte (formed in 2015), Journey Medical Corporation (formed in 2014), Mustang Bio (formed in 2015), Tamid Bio (formed in 2017) and Baergic Bio (formed in 2019).
Products
Fortress Bio’s marketed products are developed and commercialized by its subsidiary Journey Medical Corporation. These include Targadox tablets indicated for acne, eczema emollient Ceracade, wound cream Luxamend, topical corticosteroid Triderm, topical broad-spectrum antifungal solution Exelderm, Ala-Quin topical cream for skin conditions, and Ala-Scalp hydrocortisone lotion for skin conditions.
== References ==
Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗
sektorHealthcare
industriBiotechnology
karyawan78
negaraUS
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Pendapatan$63M2021-12-31 → 2025-12-31
EPS$-0.072021-12-31 → 2025-12-31
Arus Kas Bebas·2021-12-31 → 2024-12-31
Margin bersih163.3%2021-12-31 → 2025-12-31
Valuasi & Rasio
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
| Metrik | Tren 5 Tahun | FBIOP | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| P/E (TTM) | 6.2 | · | · | · | |
| P/S (TTM) | 8.2 | · | 16.1 | Kurang nilai | |
| P/B (MRQ) | 3.4 | · | 2.3 | Terlalu mahal | |
| Price / Cash Flow (Harga / Arus Kas) | -8.0 | · | · | · | |
| Harga / Nilai Buku Berwujud (MRQ) | 4.1 | · | · | · |
Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
| Metrik | Tren 5 Tahun | FBIOP | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Margin Operasi (TTM) | -42.6% | · | -461.4% | Tingkat teratas | |
| EBITDA Margin (Margin EBITDA) | -111.0% | · | -461.4% | Tingkat teratas | |
| Margin Sebelum Pajak (TTM) | 213.0% | · | -799.5% | Tingkat teratas | |
| Margin Laba Bersih (TTM) | 163.3% | · | -412.5% | Tingkat teratas | |
| ROA (TTM) | 46.9% | · | -36.6% | Tingkat teratas | |
| ROE (TTM) | 107.5% | · | -61.0% | Tingkat teratas | |
| ROIC | -138.2% | · | -64.8% | Lemah |
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
| Metrik | Tren 5 Tahun | FBIOP | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Utang / Ekuitas (MRQ) | 0.0 | · | 0.0 | Utang tinggi | |
| Rasio Lancar (MRQ) | 4.0 | · | 4.9 | Likuiditas rendah | |
| Quick Ratio (Rasio Cepat) | 2.2 | · | 2.7 | Likuiditas kuat |
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
| Metrik | Tren 5 Tahun | FBIOP | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Revenue YoY (Pendapatan YoY) | 9.7% | · | · | · | |
| Revenue CAGR 3Y (CAGR Pendapatan 3T) | -5.8% | · | · | · | |
| Revenue CAGR 5Y (CAGR Pendapatan 5T) | 6.8% | · | · | · |
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
| Metrik | Tren 5 Tahun | FBIOP | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Asset Turnover (Perputaran Aset) | 0.4 | · | 0.1 | Tingkat teratas | |
| Inventory Turnover (Perputaran Persediaan) | 1.7 | · | · | · | |
| Receivables Turnover (Perputaran Piutang) | 3.2 | · | 5.6 | Lemah | |
| Revenue / Employee (Pendapatan Tahunan ÷ karyawan (jumlah karyawan, yfinance). Turunan — bukan konsep SEC-XBRL yang tersimpan.) | ≈$811.1K | · | · | · |
nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median
Dividen Yield, rasio pembayaran, riwayat dividen, CAGR 5 tahun
Imbal Hasil Dividen0.12%
Rasio Pembayaran Dividen9.7%
Pembayaran Tahunan≈$2.34
| Tanggal ex-dividen | Jumlah | Mata Uang | Imbal Hasil |
|---|---|---|---|
| Jun 14, 2024 | $0,20 | USD | ≈14.0% |
| Mei 14, 2024 | $0,20 | USD | ≈14.2% |
| Apr 12, 2024 | $0,20 | USD | ≈13.4% |
| Mar 14, 2024 | $0,20 | USD | ≈14.0% |
| Feb 14, 2024 | $0,20 | USD | ≈14.7% |
| Jan 11, 2024 | $0,20 | USD | ≈18.0% |
| Des 14, 2023 | $0,20 | USD | ≈18.3% |
| Nov 14, 2023 | $0,20 | USD | ≈20.8% |
| Okt 12, 2023 | $0,20 | USD | ≈19.7% |
| Sep 14, 2023 | $0,20 | USD | ≈19.8% |
| Agu 14, 2023 | $0,20 | USD | ≈13.8% |
| Jul 13, 2023 | $0,20 | USD | ≈13.6% |
| Jun 14, 2023 | $0,20 | USD | ≈13.4% |
| Mei 12, 2023 | $0,20 | USD | ≈12.5% |
| Apr 13, 2023 | $0,20 | USD | ≈12.7% |
| Mar 14, 2023 | $0,20 | USD | ≈11.9% |
| Feb 14, 2023 | $0,20 | USD | ≈12.1% |
| Jan 12, 2023 | $0,20 | USD | ≈12.2% |
| Des 14, 2022 | $0,20 | USD | ≈11.6% |
| Nov 14, 2022 | $0,20 | USD | ≈11.6% |
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
-50.7%
| Periode | Laporan | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|---|
| 30 Juni 2026 | $-0.08 | $-0.20 | 60.8% | |
| 31 Maret 2026 | $-1.13 | $-0.22 | -403.6% | |
| 31 Des. 2025 | $-0.01 | $0.11 | -108.9% | |
| 30 Sep. 2025 | $0.11 | $-0.43 | 125.7% | |
| 30 Juni 2025 | $-0.50 | $-0.37 | -36.2% | |
| 31 Maret 2025 | $-0.48 | $-0.50 | 4.9% | |
| 31 Des. 2024 | $-0.75 | $-0.77 | 2.4% |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $63M | $58M | $85M | $76M | $69M | $46M | $37M | $27M | $17M | $16M | $863.0K | $0 | |
| Cost of Revenue | $21M | $21M | $23M | $31M | $32M | $15M | $11M | $6M | $4M | $790.0K | $0 | · | |
| R&D Expense | · | · | $106M | $135M | $129M | $64M | $81M | $87M | $48M | $35M | $30M | $10M | |
| SG&A Expense | $96M | $88M | $91M | $114M | $87M | $61M | $56M | $53M | $51M | $28M | $19M | $10M | |
| Operating Expenses | $133M | $168M | $227M | $279M | $257M | $140M | $147M | $147M | $107M | $82M | $51M | $21M | |
| Operating Income | $-70M | $-110M | $-142M | $-204M | $-189M | $-94M | $-111M | $-120M | $-90M | $-66M | $-51M | $-21M | |
| Interest Expense | · | · | · | · | · | · | · | · | $6M | $4M | $1M | $1M | |
| Interest Income | $2M | $3M | $3M | $1M | $649.0K | $2M | $3M | $1M | $819.0K | $298.0K | $245.0K | $662.0K | |
| Other Non-op | $18M | $1M | $-3M | $1M | $24M | $-9M | $9M | $-11M | $-8M | $-6M | $-3M | $266.0K | |
| Pretax Income | $-34M | $-121M | $-154M | $-213M | $-164M | $-103M | $-102M | $-131M | $-98M | $-71M | $-54M | · | |
| Income Tax | $-620.0K | $312.0K | $521.0K | $449.0K | $500.0K | $500.0K | $0 | $0 | $2M | $0 | $0 | · | |
| Net Income | $7M | $-46M | $-61M | $-87M | $-65M | $-47M | $-40M | $-84M | $-67M | $-55M | $-48M | $-20M | |
| EPS (Basic) | $-0.07 | $-2.69 | $-8.47 | $-15.97 | $-0.79 | · | · | · | · | · | · | · | |
| EPS (Diluted) | $-0.07 | $-2.69 | $-8.47 | $-15.97 | $-0.79 | · | · | · | · | · | · | · | |
| Shares (Basic) | 27,901,889 | 20,784,334 | 8,110,906 | 5,924,967 | 81,700,220 | · | · | · | · | · | · | · | |
| Shares (Diluted) | 27,901,889 | 20,784,334 | 8,110,906 | 5,924,967 | 81,700,220 | · | · | · | · | · | · | · | |
| EBITDA | $-70M | $-110M | $-142M | $-204M | $-189M | $-94M | $-111M | $-120M | $-100M | $-65M | $-51M | · |
Neraca
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $79M | $57M | $81M | $178M | $306M | $233M | $137M | $66M | $95M | $105M | $98M | $50M | |
| Short-term Investments | · | · | · | · | · | · | $0 | $18M | $36M | $0 | · | $20M | |
| Receivables | $30M | $10M | $15M | $28M | $23M | $24M | $14M | $5M | $8M | $2M | $0 | · | |
| Inventory | $10M | $14M | $10M | $14M | $10M | $1M | $857.0K | $678.0K | $171.0K | $203.0K | $0 | · | |
| Prepaid Expense | $5M | $7M | $10M | $10M | $7M | $7M | $4M | $7M | $6M | $9M | $2M | $702.0K | |
| Current Assets | $124M | $90M | $117M | $230M | $346M | $266M | $156M | $111M | $183M | $110M | $100M | $70M | |
| PP&E (Net) | $3M | $3M | $7M | $13M | $15M | $12M | $12M | $12M | $7M | $7M | $309.0K | $52.0K | |
| PP&E (Gross) | $8M | $15M | $15M | $25M | $24M | $19M | $17M | $15M | $8M | · | $377.0K | $94.0K | |
| Accum. Depreciation | $3M | $10M | $9M | $12M | $9M | $7M | $4M | $3M | $1M | · | $68.0K | $42.0K | |
| Goodwill | · | · | · | · | · | · | · | · | $19M | $19M | $0 | · | |
| Intangibles | $28M | $32M | $20M | $27M | $13M | $15M | $7M | $1M | $883.0K | $17M | $1M | $0 | |
| Other Non-current Assets | $401.0K | $731.0K | $4M | $973.0K | $1M | $1M | $1M | $276.0K | $258.0K | $394.0K | $43.0K | $64.0K | |
| Total Assets | $186M | $144M | $168M | $294M | $397M | $333M | $226M | $141M | $246M | $171M | $119M | $89M | |
| Accounts Payable | $14M | $32M | $35M | $57M | $47M | $11M | $35M | $34M | $27M | $2M | $10M | $366.0K | |
| Accrued Liabilities | $47M | $66M | $74M | $97M | $91M | $45M | $25M | $16M | $18M | $10M | $9M | $4M | |
| Short-term Debt | · | · | · | · | · | $0 | $7M | · | · | · | · | $0 | |
| Current Liabilities | $50M | $71M | $85M | $128M | $101M | $52M | $46M | $56M | $71M | $57M | $11M | $4M | |
| Capital Leases | $13M | $15M | $18M | $22M | $21M | $23M | $24M | $0 | · | · | · | · | |
| Deferred Tax | · | · | $233.0K | $0 | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $5M | $5M | $5M | $584.0K | $722.0K | |
| Total Liabilities | $123M | $146M | $166M | $244M | $171M | $136M | $154M | $121M | $125M | $88M | $34M | $19M | |
| Long-term Debt | $54M | $58M | $61M | $92M | $43M | $52M | $85M | $84M | $68M | $30M | $24M | $14M | |
| Total Debt | · | · | · | · | · | $0 | · | · | · | · | · | · | |
| Common Stock | $31.0K | $28.0K | $15.0K | $7.0K | $101.0K | $95.0K | $74.0K | $58.0K | $51.0K | $49.0K | $47.0K | $46.0K | |
| Paid-in Capital | $784M | $764M | $717M | $676M | $656M | $583M | $462M | $397M | $364M | $284M | $247M | $212M | |
| Retained Earnings | $-734M | $-741M | $-695M | $-634M | $-547M | $-483M | $-436M | $-396M | $-312M | $-245M | $-190M | $-142M | |
| Stockholders' Equity | $50M | $23M | $23M | $42M | $109M | $100M | $26M | $2M | $53M | $38M | $57M | $71M | |
| Liabilities + Equity | $186M | $144M | $168M | $294M | $397M | $333M | $226M | $141M | $246M | $171M | $119M | $89M | |
| Shares Outstanding | 31,364,094 | 27,908,839 | 15,093,053 | 7,366,283 | 101,435,505 | 94,877,492 | 74,027,425 | 57,845,447 | 50,991,285 | 48,932,023 | 47,147,032 | 46,494,034 |
Arus Kas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | $1M | $944.0K | $26.0K | $23.0K | |
| Stock-based Comp | $29M | $33M | $17M | $23M | $19M | $13M | $13M | $15M | $13M | $12M | $14M | $6M | |
| Deferred Tax | · | · | · | · | · | · | · | $0 | $0 | $-73.0K | $0 | $0 | |
| Amort. of Intangibles | $4M | $3M | $4M | $4M | · | $1M | $1M | · | $2M | $0 | $0 | · | |
| Other Non-cash | · | · | · | · | · | · | · | · | $-34M | $-4M | $14M | · | |
| Operating Cash Flow | $-66M | $-80M | $-128M | $-179M | $-117M | $-84M | $-95M | $-99M | $-81M | $-46M | $-20M | $-16M | |
| CapEx | · | $0 | $63.0K | $3M | $5M | $2M | $2M | $7M | $648.0K | $6M | $283.0K | $0 | |
| Investing Cash Flow | $10M | $-15M | $-2M | $-23M | $41M | $-7M | $20M | $19M | $-40M | $-6M | $8M | · | |
| Debt Issued | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Stock Issued | $1M | $4M | $2M | $6M | $9M | $46M | $21M | $10M | · | $0 | $0 | $4M | |
| Stock Repurchased | · | · | · | · | · | $70.0K | $0 | · | · | · | · | · | |
| Net Stock Activity | $1M | $4M | $2M | $6M | $9M | $47M | · | $10M | · | $0 | $0 | · | |
| Dividends Paid | $664.0K | $694.0K | $736.0K | $749.0K | $749.0K | $237.0K | $0 | · | · | · | · | · | |
| Financing Cash Flow | $77M | $71M | $33M | $75M | $149M | $172M | $147M | $51M | $150M | $43M | $61M | · | |
| Net Change in Cash | $22M | $-25M | $-98M | $-127M | $73M | $82M | $72M | $-29M | $29M | $-9M | $48M | $-50M | |
| Taxes Paid | $49.0K | $120.0K | $-55.0K | $858.0K | $993.0K | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-80M | $-128M | $-182M | $-121M | $-86M | $-97M | $-106M | $-88M | $-52M | $-21M | · | |
| Levered FCF | · | · | · | · | · | · | · | · | $-93M | · | · | · |
Profitabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -111.0% | -191.4% | -168.4% | -268.8% | -274.1% | -206.7% | -302.5% | -446.4% | -53.9% | -398.7% | -5855.3% | · | |
| Net Margin | 10.8% | -79.8% | -71.8% | -114.3% | -94.1% | -102.0% | -109.1% | -313.0% | -35.6% | -334.3% | -5611.6% | · | |
| Pretax Margin | -53.0% | -209.0% | -181.8% | -281.8% | -238.9% | -225.6% | -277.5% | -486.6% | -52.4% | · | · | · | |
| EBITDA Margin | -111.0% | -191.4% | -168.4% | -268.8% | -274.1% | -206.7% | -302.5% | -446.4% | -53.3% | -393.0% | -5852.3% | · | |
| ROA | 4.1% | -33.9% | -26.3% | -25.1% | -17.7% | -16.7% | -21.8% | -43.5% | -32.1% | -34.8% | -47.1% | · | |
| ROE | 18.8% | -203.2% | -188.7% | -115.1% | -61.9% | -73.5% | -284.8% | -309.2% | -146.9% | -115.6% | -76.0% | · | |
| ROIC | -138.2% | -486.7% | -633.5% | -488.9% | -174.0% | -94.1% | -422.7% | -6479.3% | -195.5% | · | · | · |
Likuiditas & Solvabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.5 | 1.3 | 1.4 | 1.8 | 3.4 | 5.5 | 3.4 | 2.0 | 2.7 | 1.9 | 9.4 | · | |
| Quick Ratio | 2.2 | 0.9 | 1.1 | 1.6 | 3.3 | 5.3 | 3.3 | 1.6 | 2.3 | 1.6 | 9.3 | · | |
| Debt / Equity | · | · | · | · | · | 0.0 | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | -17.3 | -17.8 | -34.1 | · |
Efisiensi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.9 | 0.1 | 0.0 | · | |
| Inventory Turnover | 1.7 | 1.7 | 2.2 | 2.6 | 5.7 | 12.9 | 13.7 | 14.4 | 19.6 | -7.8 | · | · | |
| Receivables Turnover | 3.2 | 4.5 | 3.9 | 3.0 | 2.9 | 2.8 | 3.8 | 4.1 | 39.1 | 18.0 | · | · |
Per Saham
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.59 | $0.81 | $1.49 | $0.38 | $1.07 | $1.06 | $0.35 | $0.03 | $1.03 | $0.79 | $1.21 | · | |
| Revenue / Share | $2.27 | $2.77 | $10.42 | $0.85 | · | · | · | · | · | · | · | · | |
| Cash Flow / Share | $-2.36 | $-3.86 | $-15.81 | $-2.02 | · | · | · | · | · | · | · | · | |
| Cash / Share | $2.53 | $2.05 | $5.36 | $1.61 | $3.01 | $2.46 | $1.85 | $1.13 | $2.23 | $1.80 | $2.08 | · | |
| EPS (TTM) | $-0.07 | $-2.69 | $-8.47 | $-15.97 | $-0.79 | · | · | · | · | · | · | · |
Tingkat Pertumbuhan
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 9.7% | -31.8% | 11.6% | 10.1% | 50.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -5.8% | -5.7% | 22.8% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.8% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | 22.9% | · | · | · | · | · | · | · | · | · | · | · |
Valuasi (TTM)
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $63M | $58M | $85M | $76M | $69M | $46M | $37M | $27M | $17M | $16M | $863.0K | $0 | |
| Net Income TTM | $7M | $-46M | $-61M | $-87M | $-65M | $-47M | $-40M | $-84M | $-67M | $-55M | $-48M | $-20M | |
| Market Cap | $298M | $186M | $179M | $1.95B | $2.63B | $1.84B | $1.52B | $832M | $1.16B | · | · | · | |
| Enterprise Value | · | · | · | · | · | $1.61B | · | · | · | · | · | · | |
| P/E | -135.6 | -2.5 | -1.4 | -1.1 | -32.8 | · | · | · | · | · | · | · | |
| P/S | 4.7 | 3.2 | 2.1 | 25.7 | 38.2 | 40.3 | 41.4 | 31.0 | 67.3 | · | · | · | |
| P/B | 6.0 | 8.2 | 7.9 | 46.7 | 24.2 | 18.3 | 57.8 | 449.4 | 22.1 | · | · | · | |
| P / Tangible Book | 13.4 | · | 79.4 | 134.3 | 27.3 | 21.5 | · | · | · | · | · | · | |
| P / Cash Flow | -4.5 | -2.3 | -1.4 | -10.9 | -22.5 | -22.0 | -16.0 | -8.4 | -13.6 | · | · | · | |
| P / FCF | · | -2.3 | -1.4 | -10.7 | -21.7 | -21.5 | -15.6 | -7.9 | -13.3 | · | · | · | |
| EV / EBITDA | · | · | · | · | · | -17.0 | · | · | · | · | · | · | |
| EV / FCF | · | · | · | · | · | -18.8 | · | · | · | · | · | · | |
| EV / Revenue | · | · | · | · | · | 35.2 | · | · | · | · | · | · | |
| Dividend Yield | 0.22% | 0.37% | 0.41% | 0.04% | 0.03% | 0.01% | 0.00% | · | · | · | · | · | |
| Earnings Yield | -0.74% | -40.5% | -71.4% | -90.5% | -3.0% | · | · | · | · | · | · | · | |
| Payout Ratio | 9.7% | -1.5% | -1.2% | -0.87% | -1.2% | -0.51% | · | · | · | · | · | · | |
| Annual Payout | $664.0K | $694.0K | $736.0K | $749.0K | $749.0K | $237.0K | $0 | · | · | · | · | · |
Laporan Laba Rugi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19M | $16M | $16M | $18M | $16M | $13M | $15M | $15M | $15M | $13M | $20M | $35M | $17M | $12M | $16M | $17M | |
| Cost of Revenue | $6M | $6M | $5M | $6M | $5M | $5M | $5M | $4M | $6M | $6M | $2M | $6M | $8M | $6M | $8M | $7M | |
| R&D Expense | · | · | · | · | · | · | · | $9M | $13M | $25M | · | $20M | $32M | $40M | $35M | $30M | |
| SG&A Expense | $21M | $16M | $15M | $17M | $39M | $26M | $27M | $22M | $21M | $18M | $19M | $22M | $24M | $25M | $28M | $30M | |
| Operating Expenses | $29M | $24M | $21M | $24M | $53M | $35M | $39M | $37M | $43M | $50M | $40M | $49M | $67M | $71M | $71M | $67M | |
| Operating Income | $-10M | $-8M | $-5M | $-7M | $-36M | $-22M | $-24M | $-22M | $-28M | $-37M | $-20M | $-14M | $-50M | $-59M | $-55M | $-51M | |
| Interest Income | $2M | $570.0K | $637.0K | $736.0K | $622.0K | $490.0K | $527.0K | $589.0K | $734.0K | $833.0K | $705.0K | $547.0K | $715.0K | $1M | $687.0K | $419.0K | |
| Other Non-op | $11M | $1M | $-20.0K | $18M | $-62.0K | $-12.0K | $-14.0K | $1M | $282.0K | $-21.0K | $-5M | $620.0K | $395.0K | $304.0K | $6M | $648.0K | |
| Pretax Income | $922.0K | $142M | $-6M | $9M | $-12M | $-25M | $-26M | $-27M | · | · | $-29M | $-11M | · | · | $-57M | $-53M | |
| Income Tax | $320.0K | $5M | $-646.0K | $26.0K | $0 | $0 | $243.0K | $69.0K | $0 | $0 | $380.0K | $141.0K | $0 | $0 | $449.0K | $0 | |
| Net Income | $-468.0K | $110M | $-4M | $6M | $15M | $-11M | $-7M | $-13M | $-11M | $-15M | $-9M | $-5M | $-25M | $-22M | $-27M | $-23M | |
| EPS (Basic) | $-0.08 | $3.44 | $-0.22 | $0.13 | $0.50 | $-0.48 | $-0.16 | $-0.76 | $-0.73 | $-1.04 | $-0.41 | $-0.94 | $-3.65 | $-3.47 | $-11.39 | $-4.11 | |
| EPS (Diluted) | $-0.08 | $2.82 | $-0.15 | $0.11 | $0.45 | $-0.48 | $-0.16 | $-0.76 | $-0.73 | $-1.04 | $-3.67 | $-0.94 | $-3.65 | $-0.21 | $-11.42 | $-4.11 | |
| Shares (Basic) | 31,791,173 | 31,540,595 | · | 27,244,474 | 26,879,380 | 26,450,218 | · | 19,697,290 | 18,316,874 | 17,151,945 | · | 7,498,653 | 7,377,332 | 6,792,376 | · | 5,961,663 | |
| Shares (Diluted) | 31,791,173 | 38,412,716 | · | 33,100,961 | 29,824,182 | 26,450,218 | · | 19,697,290 | 18,316,874 | 17,151,945 | · | 7,498,653 | 7,377,332 | 101,885,648 | · | 5,961,663 | |
| EBITDA | $-10M | $-8M | · | $-7M | $-36M | $-22M | · | $-22M | $-28M | $-37M | · | $-14M | $-50M | $-59M | · | $-51M |
Neraca
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $197M | $256M | $79M | $86M | $74M | $91M | $57M | $59M | $76M | $84M | $81M | $72M | $78M | $152M | $178M | $208M | |
| Receivables | $36M | $25M | $30M | $18M | $16M | $18M | $10M | $11M | $10M | $10M | $15M | $8M | $17M | $28M | $28M | $29M | |
| Inventory | $8M | $9M | $10M | $12M | $13M | $12M | $14M | $12M | $10M | $11M | $10M | $11M | $12M | $13M | $14M | $15M | |
| Prepaid Expense | $4M | $5M | $5M | $2M | $7M | $5M | $7M | $3M | $5M | $12M | $10M | $6M | $7M | $8M | $10M | $6M | |
| Current Assets | $246M | $295M | $124M | $119M | $110M | $127M | $90M | $86M | $103M | $117M | $117M | $98M | $128M | $202M | $230M | $258M | |
| PP&E (Net) | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $4M | $6M | $7M | $7M | $7M | $12M | $13M | $14M | |
| PP&E (Gross) | $7M | $7M | $8M | $8M | $8M | $8M | $15M | $15M | $15M | $15M | $15M | $15M | $15M | $25M | $25M | $25M | |
| Accum. Depreciation | $3M | $2M | $3M | $3M | $3M | $3M | $10M | $12M | $10M | $9M | $9M | $9M | $8M | $13M | $12M | $12M | |
| Intangibles | $26M | $26M | $28M | $29M | $30M | $31M | $32M | $18M | $19M | $19M | $20M | $21M | $22M | $26M | $27M | $28M | |
| Other Non-current Assets | $1M | $740.0K | $401.0K | $18M | $3M | $3M | $731.0K | $3M | $3M | $4M | $4M | $5M | $4M | $943.0K | $973.0K | $1M | |
| Total Assets | $317M | $357M | $186M | $181M | $160M | $178M | $144M | $127M | $146M | $165M | $168M | $151M | $181M | $264M | $294M | $324M | |
| Accounts Payable | $12M | $14M | $14M | $19M | $20M | $28M | $32M | $34M | $38M | $42M | $35M | $45M | $49M | $66M | $57M | $56M | |
| Accrued Liabilities | $49M | $93M | $47M | $45M | $49M | $66M | $66M | $64M | $69M | $76M | $74M | $81M | $99M | $105M | $97M | $94M | |
| Short-term Debt | $5M | $2M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $62M | $103M | $50M | $54M | $58M | $74M | $71M | $70M | $76M | $88M | $85M | $97M | $129M | $129M | $128M | $106M | |
| Capital Leases | $11M | $12M | $13M | $13M | $13M | $14M | $15M | $15M | $16M | $18M | $18M | $19M | $20M | $21M | $22M | $21M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | |
| Other Non-current Liabilities | $3M | $2M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Total Liabilities | $111M | $154M | $123M | $116M | $123M | $146M | $146M | $140M | $160M | $169M | $166M | $164M | $197M | $244M | $244M | $222M | |
| Long-term Debt | $35M | $38M | $52M | $48M | $50M | $56M | $58M | $52M | $67M | $61M | $61M | $46M | $55M | $92M | $92M | $91M | |
| Total Debt | $5M | $2M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $33.0K | $33.0K | $31.0K | $31.0K | $30.0K | $30.0K | $28.0K | $28.0K | $23.0K | $19.0K | $15.0K | $9.0K | $132.0K | $130.0K | $7.0K | $108.0K | |
| Paid-in Capital | $788M | $786M | $784M | $786M | $780M | $774M | $764M | $755M | $739M | $733M | $717M | $702M | $699M | $693M | $676M | $669M | |
| Retained Earnings | $-624M | $-624M | $-734M | $-730M | $-736M | $-751M | $-741M | $-734M | $-721M | $-710M | $-695M | $-686M | $-681M | $-656M | $-634M | $-607M | |
| Stockholders' Equity | $164M | $162M | $50M | $56M | $44M | $22M | $23M | $21M | $18M | $23M | $23M | $17M | $19M | $38M | $42M | $62M | |
| Liabilities + Equity | $317M | $357M | $186M | $181M | $160M | $178M | $144M | $127M | $146M | $165M | $168M | $151M | $181M | $264M | $294M | $324M | |
| Shares Outstanding | 33,311,012 | 33,186,671 | 31,364,094 | 31,005,170 | 29,752,795 | 29,554,966 | 27,908,839 | 27,584,600 | 22,587,038 | 19,375,343 | 15,093,053 | 8,937,587 | 131,657,369 | 130,417,161 | 7,366,283 | 108,259,353 |
Arus Kas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $3M | $2M | $2M | $3M | $17M | $6M | $16M | $7M | $5M | $5M | $4M | $4M | $4M | $5M | $6M | $7M | |
| Amort. of Intangibles | $969.0K | $1M | $1M | $1M | $1M | $1M | $982.0K | $814.0K | $814.0K | $814.0K | $815.0K | $814.0K | $1M | $1M | $1M | $1M | |
| Operating Cash Flow | $-59M | $204M | $-13M | $-6M | $-28M | $-20M | $-13M | $-20M | $-22M | $-25M | $-35M | $-17M | $-33M | $-43M | $-48M | $-43M | |
| CapEx | · | · | · | · | · | · | · | $0 | · | · | $28.0K | $1.0K | $34.0K | $0 | $91.0K | $980.0K | |
| Investing Cash Flow | $-79.0K | $0 | $0 | $3M | $6M | $1M | $-15M | $0 | $0 | $0 | $-63.0K | $5M | $-2M | $-5M | $-391.0K | $-893.0K | |
| Stock Issued | · | $0 | $0 | $0 | $-1.0K | $1M | $340.0K | $568.0K | $2M | $894.0K | $-15.0K | $888.0K | $721.0K | $447.0K | $303.0K | $223.0K | |
| Net Stock Activity | · | $0 | · | · | · | $1M | · | · | · | $894.0K | · | · | · | $447.0K | · | · | |
| Dividends Paid | · | $0 | $166.0K | $166.0K | $166.0K | $166.0K | $166.0K | $176.0K | $176.0K | $176.0K | $180.0K | $185.0K | $185.0K | $186.0K | $186.0K | $188.0K | |
| Financing Cash Flow | $91.0K | $-27M | $6M | $15M | $5M | $52M | $26M | $3M | $14M | $28M | $44M | $-3M | $-30M | $22M | $19M | $4M | |
| Net Change in Cash | $-59M | $176M | $-7M | $12M | $-17M | $34M | $-2M | $-17M | $-8M | $2M | $9M | $-14M | $-66M | $-26M | $-30M | $-40M | |
| Taxes Paid | · | · | $0 | $0 | · | · | $5.0K | $0 | $115.0K | $0 | $-38.0K | $35.0K | $52.0K | $-104.0K | $-604.0K | $1M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | · | · | · | · | $-43M | · | · |
Profitabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -53.5% | -48.2% | · | -38.6% | -222.2% | -169.8% | · | -151.0% | -186.5% | -280.6% | · | -39.6% | -288.2% | -473.6% | · | -307.0% | |
| Net Margin | -2.5% | 688.2% | · | 33.2% | 94.3% | -80.5% | · | -88.0% | -73.5% | -118.3% | · | -14.5% | -142.5% | -173.3% | · | -136.2% | |
| Pretax Margin | 4.9% | 887.2% | · | 50.2% | · | · | · | -182.0% | · | · | · | -30.4% | · | · | · | · | |
| EBITDA Margin | -53.5% | -48.2% | · | -38.6% | -222.2% | -169.8% | · | -151.0% | -186.5% | -280.6% | · | -39.6% | -288.2% | -473.6% | · | -307.0% | |
| ROA | -0.20% | 41.3% | · | 3.8% | 10.1% | -6.2% | · | -9.3% | -6.7% | -7.2% | · | -2.1% | -9.1% | -6.4% | · | -6.2% | |
| ROE | -0.45% | 119.7% | · | 15.2% | 50.1% | -46.8% | · | -68.0% | -60.2% | -50.7% | · | -12.9% | -51.8% | -31.8% | · | -29.2% | |
| ROIC | -3.9% | -4.5% | · | -12.2% | · | · | · | -104.7% | · | · | · | -83.6% | · | · | · | · |
Likuiditas & Solvabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.0 | 2.9 | · | 2.2 | 1.9 | 1.7 | · | 1.2 | 1.4 | 1.3 | · | 1.0 | 1.0 | 1.6 | · | 2.4 | |
| Quick Ratio | 3.8 | 2.7 | · | 1.9 | 1.6 | 1.5 | · | 1.0 | 1.1 | 1.1 | · | 0.8 | 0.7 | 1.4 | · | 2.2 | |
| Debt / Equity | 0.0 | 0.0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Efisiensi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.6 | 0.6 | · | 0.5 | 0.4 | 0.4 | · | 0.5 | 0.6 | 0.6 | · | 0.5 | 0.6 | 0.4 | · | 0.5 | |
| Receivables Turnover | 0.7 | 0.7 | · | 1.2 | 1.3 | 0.9 | · | 1.6 | 1.1 | 0.7 | · | 1.9 | 0.8 | 0.4 | · | 0.5 |
Per Saham
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $4.93 | $4.89 | · | $1.80 | $1.48 | $0.75 | · | $0.77 | $0.79 | $1.19 | · | $1.87 | $0.14 | $0.29 | · | $0.57 | |
| Revenue / Share | $0.59 | $0.42 | · | $0.53 | $0.55 | $0.50 | · | $0.74 | $0.81 | · | · | $4.63 | $0.16 | $0.12 | · | $0.18 | |
| Cash Flow / Share | · | $5.31 | · | · | · | $-0.74 | · | · | · | · | · | · | · | $-0.42 | · | · | |
| Cash / Share | $5.90 | $7.71 | · | $2.78 | $2.50 | $3.09 | · | $2.13 | $3.37 | $4.32 | · | $8.09 | $0.59 | $1.17 | · | $1.92 | |
| Dividend / Share | · | · | · | · | · | · | · | $0.00 | · | · | · | · | · | · | · | · | |
| EPS (TTM) | $2.70 | $3.23 | · | $-0.08 | $-0.95 | $-2.13 | · | $-6.20 | $-6.38 | $-9.30 | · | $-16.22 | $-19.39 | $-16.00 | · | $-4.93 |
Valuasi (TTM)
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $68M | $66M | · | $62M | $59M | $58M | · | $63M | $83M | $85M | · | $81M | $63M | $64M | · | $78M | |
| Net Income TTM | $112M | $128M | · | $4M | $-15M | $-41M | · | $-49M | $-41M | $-55M | · | $-78M | $-96M | $-92M | · | $-91M | |
| Market Cap | $670M | $462M | · | $285M | $229M | $178M | · | $150M | $359M | $322M | · | $105M | $2.30B | $2.40B | · | $2.03B | |
| Enterprise Value | $478M | $208M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | 7.4 | 4.3 | · | -115.0 | -8.1 | -2.8 | · | -0.9 | -2.5 | -1.8 | · | -0.7 | -0.9 | -1.1 | · | -3.8 | |
| P/S | 9.8 | 7.0 | · | 4.6 | 3.9 | 3.1 | · | 2.4 | 4.3 | 3.8 | · | 1.3 | 36.7 | 37.4 | · | 26.2 | |
| P/B | 4.1 | 2.8 | · | 5.1 | 5.2 | 8.0 | · | 7.1 | 20.1 | 14.0 | · | 6.3 | 124.5 | 63.5 | · | 32.9 | |
| P / Tangible Book | 4.8 | 3.4 | · | 10.5 | 16.1 | · | · | 45.4 | · | 90.5 | · | · | · | 205.7 | · | 61.1 | |
| P / Cash Flow | · | 2.3 | · | · | · | -9.1 | · | · | · | -12.7 | · | · | · | -55.5 | · | · | |
| EV / Revenue | 7.0 | 3.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend Yield | 0.07% | 0.11% | · | 0.23% | 0.29% | 0.39% | · | 0.47% | 0.20% | 0.23% | · | 0.71% | 0.03% | 0.03% | · | 0.04% | |
| Earnings Yield | 13.4% | 23.2% | · | -0.87% | -12.3% | -35.4% | · | -113.8% | -40.1% | -56.0% | · | -138.3% | -110.8% | -87.0% | · | -26.3% | |
| Payout Ratio | · | 0.00% | · | · | · | -1.6% | · | · | · | -1.1% | · | · | · | -0.86% | · | · | |
| Annual Payout | $498.0K | $498.0K | · | $664.0K | $674.0K | $684.0K | · | $708.0K | $717.0K | $726.0K | · | $742.0K | $745.0K | $748.0K | · | $750.0K |
Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
| Metrik | 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|
| Pendapatan | $63M | · | · | $58M | · |
| Margin Operasi % | -111.0% | · | · | -191.4% | · |
| Laba Bersih | $7M | · | · | $-46M | · |
| EPS Dilusian | $-0.07 | · | · | $-2.69 | · |
| Metrik | 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|
| Rasio Lancar | 2.5 | · | · | 1.3 | · |
| Rasio Cepat | 2.2 | · | · | 0.9 | · |
| Metrik | 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|
| Arus Kas Bebas | · | · | · | $-80M | · |
Aktivis & pemilik 5%+ 3 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| Fortress Biotech, Inc. ×2 pengajuan | 3 Jan. 2025 | 12,40% | Amandemen | · | SEC |
| Lindsay A Rosenwald, M.D. | 27 Jan. 2017 | · | Pengajuan awal | · | SEC |
| Michael S. Weiss | 28 Jan. 2016 | · | Pengajuan awal | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Orang dalam perusahaan 10 orang dalam · 4 pejabat · 8 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Lindsay A. Rosenwald, M.D. | President and CEO | 1 Jan. 2017 A | 5.857.168 | 0 | 0 | $0 |
| David Jin | Chief Financial Officer | 1 Okt. 2026 A | 1.652.761 | 0 | 0 | $0 |
| Michael S Weiss | Exec. VC - Strategic Dev. | 1 Jan. 2017 A | 8.001.170 | 0 | 0 | $0 |
| George Avgerinos | SVP, Biologics Operations | 16 Sep. 2016 S | 259.088 | 0 | 0 | $0 |
| Kevin Lorenz | Direktur | 1 Jan. 2026 A | 101.009 | 0 | 0 | $0 |
| Dov Klein | Direktur | 14 Juli 2017 A | 201.668 | 0 | 0 | $0 |
| Jimmie Harvey | Direktur | 10 Maret 2017 A | · | 0 | 0 | $0 |
| Malcolm Hoenlein | Direktur | 10 Maret 2017 A | · | 0 | 0 | $0 |
| Eric K Rowinsky | Direktur | 1 Jan. 2017 A | 350.000 | 0 | 0 | $0 |
| Jay J Lobell | Direktur | 1 Jan. 2017 A | 686.000 | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
FBIOP Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
peringkat · 8 analis
BELI
2 25,0%
Beli Kuat
5 62,5%
Beli
1 12,5%
Tahan
0 0,0%
Jual
0 0,0%
Jual Kuat
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| FBIOP | $298M | -135.6 | 9.7% | 10.8% | 18.8% | · |
| ALDX | $312M | -9.2 | · | · | -68.0% | · |
| SPRO | $131M | 15.5 | 39.2% | 12.8% | 18.7% | · |
| RNTX | · | -0.6 | · | · | · | · |
| GRML | · | · | · | · | -104.9% | · |
| FBIO | · | · | · | · | · | · |
| XBIT | · | -1.6 | · | · | · | · |
| APLM | · | -2.5 | · | -128.7% | -1305.4% | · |
| IBIO | $97M | -5.5 | -75.0% | -33044.0% | -65.7% | · |
| GOSS | $724M | -4.1 | -57.7% | -351.5% | 201.8% | · |
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Sumber: SEC 10-Q diajukan Agu 13, 2026